Feb 13, 2020 - Health

The boom times of insulin sales

Photo: Kerem Yucel/AFP via Getty Images

The three drug companies that control the insulin market have seen their net sales climb over the past 12 years even as they have had to agree to bigger discounts, according to an Axios analysis of insulins sold by Eli Lilly, Novo Nordisk and Sanofi.

The big picture: Drug manufacturers have largely blamed the broken insulin market — where many people with diabetes are rationing their medication — on other actors within the supply chain. But insulin makers have still been able to collect more money overall and retain their power over the market.

Data: Company documents; Chart: Andrew Witherspoon/Axios

By the numbers: Net global insulin sales, after accounting for rebates, rose by at least 80% from 2008 through 2019 for each of the big three companies.

  • There's a lot of variation in sales by brand (see all of them).
  • For example, revenue from Sanofi's Lantus fell in 2016, after its patent expired and CVS and UnitedHealth excluded it from their coverage lists. Sales shifted to a competitor, Eli Lilly's Basaglar.

Between the lines: Revenue is a function of price and quantity, and both have risen.

  • Insulins' list prices have gone up drastically over the past two decades. List prices matter a lot for the uninsured and people with less generous health plans.
  • Net prices have not increased as much, and for some insulins they have dropped, because pharmacy benefit managers have extracted higher discounts, called rebates, in exchange for giving certain insulins preferred coverage status.
  • The growing prevalence of diabetes has led to higher insulin use, but outside data shows total prescriptions and daily insulin use have grown modestly over the past several years. Eli Lilly, Novo Nordisk and Sanofi all declined to say how many insulin vials and pens they have sold.

The intrigue: Insulin sales are rising even though many of the drugs' patents have expired.

  • Humalog, NovoLog and Lantus all lost patent protection over the past several years. Their revenues have dipped, but they still generate more than $2.5 billion each in net sales.
  • Patents for Humulin and Novolin expired more than 15 years ago, but they still generate more than $1 billion each in net sales.
  • Even though some patents have lapsed, developing cheaper insulins is difficult and costly, and the incumbent players are fighting regulatory agencies to delay competition.

What they're saying: Eli Lilly, Novo Nordisk and Sanofi submitted statements but did not address some questions about their net sales.

  • Eli Lilly attributed higher sales to more people getting diagnosed with diabetes.
  • Novo Nordisk said "a lot of factors like increase of prevalence" contributed to higher sales.
  • Sanofi focused on its lower net price and lower sales in recent years, but not factors that led to higher sales over time.

The bottom line: Discounts and price negotiations have inconvenienced, not fundamentally hurt, insulin makers. And patients, along with the public, are footing the bills.

Go deeper

A tale of two drug patent cases

Biogen scored a major patent win with its multiple sclerosis drug. Photo: John Tlumacki/The Boston Globe via Getty Images

The U.S. Patent and Appeal Board this week handed down mixed rulings in a pair of important cases involving drug patents.

Why it matters: The patent system is the foundation of drug companies' ability to keep their prices high, and these specific rulings will affect access and cost for two drugs that treat serious conditions — HIV and multiple sclerosis.

Go deeperArrowFeb 7, 2020 - Health

California power crisis charges up battery sales

Close-up of screen terminal with wires on the negative terminal of a 12 volt solar photovoltaic battery bank. Photo: Smith Collection/Gado/Getty Images

Sales of residential batteries in California are expected to quadruple this year to over 50,000 storage systems, the research firm BloombergNEF said in a short new analysis.

Why it matters: It adds specifics to the expectation that power outages — notably widespread blackouts by utilities seeking to cut wildfire risk — will juice sales.

Cannabis-based drug is going mainstream

Epidiolex has a list price of $1,310 per bottle. Photo: GW Pharmaceuticals

Sales of the epilepsy drug Epidiolex hit almost $300 million in 2019, GW Pharmaceuticals reported Tuesday. Sales are expected to surpass a half-billion dollars this year as the drug gains more insurance coverage in Europe.

Why it matters: Epidiolex is the first FDA-approved medication made from a substance in cannabis, and it's starting to take off.

Go deeperArrowFeb 26, 2020 - Health